HIV Post-Exposure Prophylaxis in Patients who May Become Pregnant

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

2 posts / 0 new
Log in or register to post comments
Last post
Tue, 08/14/2018 - 11:36
#1
Christina M. Di...
Christina M. Di Donato's picture
Offline
Last seen: 5 years 10 months ago
Joined: 08/09/2018 - 11:29
HIV Post-Exposure Prophylaxis in Patients who May Become Pregnant

Hello,

Back in May, the CDC released an interim statement about the possibility of neural tube defects in infants exposed to dolutegravir in utero. Here's the document: https://www.cdc.gov/hiv/pdf/basics/cdc-hiv-dolutegravir-alert.pdf

Since PEP is such a short course of therapy, the question is whether dolutegravir should be used in patients where pregnancy is only suspected (e.g. sexual assault victims, unprotected sex with someone whose HIV status is questionable, etc.)

My institution currently uses dolutegravir+emtricitabine+tenofovir disoproxil fumarate. What policies do you all employ at your institutions? Thanks for the input.

Tags: 

Top